Marc TessierLavigne - Regeneron Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;padding-top: 25px;;'>RP</div>
REGN -- USA Stock  

Report: 4th of August 2020  

  Director
Dr. Marc TessierLavigne, Ph.D., is Independent Director of the Company. He was the President of Stanford University since September 2016. Before assuming his role at Stanford, he served as the President of The Rockefeller University and a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from March 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. TessierLavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of London and Canada. Dr. TessierLavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc.
Age: 58  Director Since 2011  Ph.D    
914 847-7000  www.regeneron.com
TessierLavigne distinguished scientific and academic background, and his significant industry experience, including experience in senior scientific leadership roles at a leading biopharmaceutical company, led the board to conclude that Dr. TessierLavigne should serve as a director.

Marc TessierLavigne Latest Insider Activity

Regeneron Pharmaceuticals Management Efficiency

Regeneron Pharmaceuticals has return on total asset (ROA) of 10.77 % which means that it generated profit of $10.77 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 21.13 %, meaning that it created $21.13 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Regeneron Pharmaceuticals Return on Invested Capital is quite stable at the moment as compared to the past year. The company's current value of Return on Invested Capital is estimated at about 0.25. Return on Sales is projected to rise to 0.27 this year, although the value of Return on Investment will most likely fall to 19.90. Regeneron Pharmaceuticals Total Assets Per Share are quite stable at the moment as compared to the past year. The company's current value of Total Assets Per Share is estimated at about 144.86. Asset Turnover is projected to rise to 0.61 this year, although the value of Net Current Assets as percentage of Total Assets will most likely fall to 36.01. Total Liabilities is projected to rise to about 4 B this year. Current Liabilities is projected to rise to about 2.3 B this year
The company currently holds 715.2 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Regeneron Pharmaceuticals has a current ratio of 4.13, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Patrick OSullivanAllergan Plc
2013
Jacqualyn FousePerrigo Company Plc
2012
David GreenwayVertex Pharmaceuticals Incorpor
2017
Ellen HoffingPerrigo Company Plc
2008
Robert ScullyZoetis Inc
2013
Dan LittmanPfizer Inc
2018
Ronald BlaylockPfizer Inc
2017
Ashok GangulyDr Reddys Laboratories
2009
Anupam PuriDr Reddys Laboratories
2002
Theodore SamuelsPerrigo Company Plc
2017
Donal OConnorPerrigo Company Plc
2014
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Shikha SharmaDr Reddys Laboratories
2019
Suzanne JohnsonPfizer Inc
2007
Michael GallagherAllergan Plc
2015
Bharat DoshiDr Reddys Laboratories
2016
Laurie BrlasPerrigo Company Plc
2016
Thomas FreymanAllergan Plc
2018
Robert HuginAllergan Plc
2019
Stephen SangerPfizer Inc
2009

Company Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on BATS Exchange. It employs 8030 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,030 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Equity Search Now

   

Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
3 days ago
Traded for 8.62
GM   
Sold over 100 shares of
3 days ago
Traded for 25.24
XOM   
Sold over 60 shares of
3 days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
3 days ago
Traded for 28.82
MSFT   
Sold few shares of
3 days ago
Traded for 206.26
Additionally, take a look at Your Equity Center. Please also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page